Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $37.93

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $37.9286.

GMAB has been the topic of a number of recent analyst reports. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Truist Financial initiated coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price target on the stock. Wolfe Research initiated coverage on shares of Genmab A/S in a research report on Friday, March 27th. They issued an “outperform” rating and a $32.00 price target on the stock. Wells Fargo & Company initiated coverage on shares of Genmab A/S in a research report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price target on the stock. Finally, Weiss Ratings lowered shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th.

Hedge Funds Weigh In On Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC boosted its position in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after buying an additional 616 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Genmab A/S during the first quarter worth approximately $34,000. NewEdge Advisors LLC lifted its position in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $26.11 on Tuesday. The stock has a market cap of $16.28 billion, a P/E ratio of 19.78, a PEG ratio of 1.66 and a beta of 0.85. The company’s 50-day simple moving average is $26.22 and its 200 day simple moving average is $28.80. Genmab A/S has a twelve month low of $20.23 and a twelve month high of $35.43. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.